[HTML][HTML] An NK-like CAR T cell transition in CAR T cell dysfunction
Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in
hematological malignancies but remains ineffective in solid tumors, due in part to CAR T cell …
hematological malignancies but remains ineffective in solid tumors, due in part to CAR T cell …
An NK-like CAR T cell transition in CAR T cell dysfunction
CR Good, MA Aznar, S Kuramitsu, P Samareh… - Cell, 2021 - profiles.wustl.edu
Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in
hematological malignancies but remains ineffective in solid tumors, due in part to CAR T cell …
hematological malignancies but remains ineffective in solid tumors, due in part to CAR T cell …
[HTML][HTML] An NK-like CAR T cell transition in CAR T cell dysfunction
CR Good, MA Aznar, S Kuramitsu, P Samareh… - Cell, 2021 - Elsevier
Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in
hematological malignancies but remains ineffective in solid tumors, due in part to CAR T cell …
hematological malignancies but remains ineffective in solid tumors, due in part to CAR T cell …
[HTML][HTML] An NK-like CAR T cell transition in CAR T cell dysfunction
CR Good, MA Aznar, S Kuramitsu, P Samareh… - Cell, 2021 - cell.com
Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in
hematological malignancies but remains ineffective in solid tumors, due in part to CAR T cell …
hematological malignancies but remains ineffective in solid tumors, due in part to CAR T cell …
An NK-like CAR T cell transition in CAR T cell dysfunction.
CR Good, MA Aznar, S Kuramitsu, P Samareh… - Cell, 2021 - europepmc.org
Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in
hematological malignancies but remains ineffective in solid tumors, due in part to CAR T cell …
hematological malignancies but remains ineffective in solid tumors, due in part to CAR T cell …
An NK-like CAR T cell transition in CAR T cell dysfunction
CR Good, MA Aznar, S Kuramitsu, P Samareh… - Cell, 2021 - pubmed.ncbi.nlm.nih.gov
Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in
hematological malignancies but remains ineffective in solid tumors, due in part to CAR T cell …
hematological malignancies but remains ineffective in solid tumors, due in part to CAR T cell …
An NK-like CAR T cell transition in CAR T cell dysfunction
CR Good, MA Aznar, S Kuramitsu, P Samareh… - paper.sciencenet.cn
美国宾夕法尼亚大学Carl H. June, Regina M. Young 和Shelley L. Berger
三位研究人员共同合作取得了重要的进展, 他们研究发现CAR T 细胞功能障碍与CAR T …
三位研究人员共同合作取得了重要的进展, 他们研究发现CAR T 细胞功能障碍与CAR T …
An NK-like CAR T cell transition in CAR T cell dysfunction
CR Good, MA Aznar, S Kuramitsu, P Samareh… - Cell, 2021 - escholarship.org
Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in
hematological malignancies but remains ineffective in solid tumors, due in part to CAR T cell …
hematological malignancies but remains ineffective in solid tumors, due in part to CAR T cell …
[HTML][HTML] An NK-like CAR T cell transition in CAR T cell dysfunction
CR Good, MA Aznar, S Kuramitsu, P Samareh… - Cell, 2021 - ncbi.nlm.nih.gov
Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in
hematological malignancies but remains ineffective in solid tumors, due in part to CAR T cell …
hematological malignancies but remains ineffective in solid tumors, due in part to CAR T cell …
[引用][C] An NK-like CAR T cell transition in CAR T cell dysfunction
CR Good, MA Aznar, S Kuramitsu, P Samareh… - Cell, 2021 - cir.nii.ac.jp
An NK-like CAR T cell transition in CAR T cell dysfunction | CiNii Research CiNii 国立情報学
研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …
研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …